Suchergebnisse

Though forensic genetic technologies are upheld as important tools of justice; the development of these technologies has been accomplished through the ongoing genetic servitude of Indigenous Peoples. Forensic Colonialism explores how these controversial methods serve only privileged populations, and keep others exploited and criminalized.

Current therapies for most human genetic diseases are inadequate. In response to the need for effective treatments, modern molecular genetics is providing tools for an unprecedented new approach to the treatment of diseases; e.g. the direct manipulation of mutant genes or the input on new therapeutic genes. The treatment of human disease by gene transfer has now moved from the theoretical to the practical realm. With the initiation of clinical trials involving somatic gene therapy in different countries, a critical assessment of the different aspects involved with this new technique is necessary. This volume provides an overview on all these interdisciplinary aspects by some well known experts all over the world

The potential use of CRISPR-Cas9 and other new gene editing technologies to alter the DNA of human beings raises a host of questions. Some questions are about safety: Can these technologies be deployed without posing an unreasonable risk of physical harm to current and future generations? Can all physical risks be adequately assessed and responsibly managed? Gene editing technologies also raise other, equally if not more difficult, questions that touch on deeply held, personal, cultural, and societal values: Might such technologies redefine what it means to be healthy, normal, or cherished? Might they undermine relationships between parents and children or exacerbate the gap between the haves and have-nots? The broadest form of this second kind of question about the impact of gene editing on values is the focus of this work.

The Human Genome Project is an expensive, ambitious, and controversial attempt to locate and map every one of the approximately 100,000 genes in the human body. If it works, and we are able, for instance, to identify markers for genetic diseases long before they develop, who will have the right to obtain such information? What will be the consequences for health care, health insurance, employability, and research priorities? And, more broadly, how will attitudes toward human differences be affected, morally and socially, by the setting of a genetic "standard"?The compatibility of individual rights and genetic fairness is challenged by the technological possibilities of the future, making it difficult to create an agenda for a "just genetics." Beginning with an account of the utopian dreams and authoritarian tendencies of historical eugenics movements, this book's nine essays probe the potential social uses and abuses of detailed genetic information. Lucid and wide-ranging, these contributions will provoke discussion among bioethicists, legal scholars, and policy makers

"In 2000, the National Human Genome Research Institute announced the completion of a "draft" of the human genome, the sequence information of nearly all 3 billion base pairs of DNA. In the wake of this major scientific accomplishment, the focus on the genetic basis of disease has sparked many controversies as questions are raised about radical preventative therapies, the role of race in research, and the environmental origins of illness. In The Material Gene, Kelly Happe explores the cultural and social dimensions of our understandings of genomics, using this emerging field to examine the physical manifestation of social relations. Situating contemporary genomics medicine and public health within a wider history of eugenics, Happe examines how the relationship between heredity and dominant social and economic interests has shifted along with transformations in gender and racial politics, social movement, and political economy. Happe demonstrates that genomics is a type of social knowledge, relying on cultural values to attach meaning to the body. The Material Gene situates contemporary genomics within a history of genetics research yet is attentive to the new ways in which knowledge claims about heredity, race, and gender emerge and are articulated to present-day social and political agendas. Kelly E. Happe is assistant professor of communication studies and womens studies at the University of Georgia"--

Most public discussion has focused on those effects of genetic research that are considered in some way unwanted or unpleasant. For example, there has been much debate concerning the risks and the ethical appropriateness of genetic screening, gene therapy, and agricultural applications based on genetic techniques. It often claimed that genetic research may cause new problems such as genetic discrimination, stigmatization, environmental risks, or mistreatment of animals. Genes and Morality: New Essays adopts a critical attitude toward genetic research, on both a theoretical and a practical level. It presents some of the most important problems in the ethics of genetic engineering, including the questions of genetic health and disease, genetic testing, responsibility for health, patenting non-human and human life, and problems related to the disclosure of genetic information. The aim of the book is to focus on real ethical and conceptual issues. Consider, for instance, the concept of genetic disease. As one of the contributors, Ingmar Pörn, writes, fear of genetic disease, or anxiety, is not itself a disease any more than fear of becoming unemployed is a disease. Alleviating such emotions is not a medical task to be discharged by drug therapy. The book also examines the philosophical foundations of these issues by discussing the most influential bioethical theories of today, including utilitarianism and principlism

Cover -- Half Title Page -- Title Page -- Copyright Page -- Declaration -- About the Editor -- Table of Contents -- List of Contributors -- List of Abbreviations -- Preface -- Chapter 1 Gene Therapy: Progress and Predictions -- Abstract -- Introduction -- Gene Therapy Remains A Delivery Challenge -- Replacement Gene Therapy Using Bone Marrow Transplantation -- Direct Injection of Adeno-Associated Virus Vectors For Gene Replacement Therapy -- Gene Therapy to Treat Cancer And Infectious Disease -- Gene Therapy as a Different Formulation of a Conventional Medicine -- Where Will Gene Therapy Be In Another 25 Years? -- References -- Chapter 2 Advances In Non-Viral DNA Vectors For Gene Therapy -- Abstract -- Introduction to Gene Therapy -- Challenges of Using Plasmid Vectors For Gene Therapy -- Improvements to Plasmid Vectors -- Development of Minicircles and Minivectors -- Therapeutic Needs Best Addressed by Minimized Vectors -- Concluding Remarks: Moving Minimized Non-Viral DNA Vectors Into The Clinic -- Acknowledgments -- Author Contributions -- References -- Chapter 3 Gene Delivery Technologies For Efficient Genome Editing: Applications In Gene Therapy -- Abstract -- Introduction -- Viral-Based Vectors -- Non-Viral-Based Vectors -- Acknowledgements -- References -- Chapter 4 Alpharetroviral Vectors: From A Cancer-Causing Agent To A Useful Tool For Human Gene Therapy -- Abstract -- Introduction -- History of (Alpha-) Retroviruses -- From The Virus To The Vector -- On The Road To Clinical Applicability: Production Perspectives of Alpharetroviral Vectors -- From Bench To Bedside: Regulatory Requirements For Clinical Translation -- Potential Future Clinical Applications of Alpharetroviral Sin Vectors -- Conclusions And Outlook -- Acknowledgments -- References And Notes

"Human exploration of space contains many ethical challenges. Future long-term space missions will generate specific problems and place new demands on humanity. One of them is the concept of human enhancement, primarily through gene editing, for the implementation of long-term space missions. In this book, I hypothesize that large-scale application of human enhancement may be necessary to enable space exploration and exploitation. The book discusses the many arguments for and against human genetic modification for space missions. It also considers the most controversial type of modification, germline gene editing. In the book I present many arguments in favor of applying even radical and considered controversial forms of human enhancements today. The book shows that the environment of future space missions is a unique and different ethical environment from Earth's and requires a modified bioethical approach. The bioethics of space missions should be syncretic, issue-driven, and highly dependent on the purpose of space missions. In the book, I point out the importance of discussing future scenarios of human development. Space bioethics is presented as part of futures studies. The book considers futures of humanity in space that are possible, probable, preferable, but also dystopian. The aim of these considerations is to prevent the development of these worst-case scenarios. The book suggests that we should look to the development of biomedicine with greater optimism and hope. Human enhancement via gene editing for space missions is presented as a pragmatic tool rooted in the principle of well-being"--

Human gene patents are patents on human genes that have been removed from human bodies and scientifically isolated and manipulated in a laboratory. The U.S. Patent and Trademark Office (the USPTO) has issued thousands of patents on such genes, and patents have also been granted by the European Patent Office, (the EPO). Legal and moral justification, however, are not identical, and it is possible for a legal decision to be immoral although consistent with legal precedent and procedure. So, it is surprising to learn that some people believe that the legal justification of human gene patents can remove the most serious moral objections to them. Yet, those who are well-versed in patent law often believe that confusion over some quite basic legal and scientific facts accounts for moral objections to such patents and, in particular, for the belief that they justify the ownership of one person by another. Once these confusions are removed, they contend, we will see that there is nothing especially alarming about patents on human genes, and no reason to believe them immoral. Such claims seem especially surprising because the morality of an invention is generally supposed to have little role in decisions about whether or not an invention deserves a patent under U.S. law. Although the European Patent Convention's article 53 (a) prohibits patenting inventions, the publication or exploitation of which would be contrary to public order or morality, it turns out that this clause rarely justifies withholding a patent from an invention that otherwise meets legal criteria. Thus, although more than 320,000 patents have been granted by the EPO since its creation, this clause has never been used successfully to strike down a claim for a patent. Indeed, Ulrich Schatz explains, "Poisons, explosives, extremely dangerous chemical substances, devices used in nuclear power stations, agro-chemicals, pesticides and many other things which can threaten human life or damage the environment have been patented, despite the existence of the public order and morality bar" in almost all European countries. Indeed, this paper shows, while ethical objections to human gene patents are often controversial, they need not be unreasonable, nor need they depend on mistaken assumptions about patent law. Rather, they may reflect familiar ethical concerns about the dominance of commercial imperatives in modern societies; concerns about the disparities in power and wealth amongst individuals and countries; and concerns about the lack of public discussion, transparency and accountability surrounding significant changes in people's rights, status and opportunities. Hence, I conclude, ethical concerns cannot be easily dismissed and, indeed, point to the need to think harder about the nature and justification of patent law, itself.